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A case of refractory cutaneous lichenoid sarcoidosis successfully treated with tranilast 
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To the Editor: We would like to report a case of cutaneous lichenoid sarcoidosis, which 
was refractory to the conventional therapy but treated successfully with tranilast. 
A 76-year-old Japanese man was referred to our clinic complaining of 
asymptomatic papules and erythematous plaques on his extremities and trunk (Fig. 
1a-c). His health was good in general and he didn’t take any oral medication. 
Superficial lymph nodes were not enlarged, and there was no abnormality on urinalysis, 
peripheral blood count or blood chemistry including blood sugar, hemoglobinA1c, 
angiotensin converting enzyme, and calcium. No abnormal finding was observed on 
chest radiography, chest and abdominal CT scans, electrocardiogram, and 
ophthalmologic examinations. QuantiFERON-TB Gold, an indirect diagnostic test for 
latent tuberculosis (TB) and active TB infections, was negative, either. The histology 
showed non-caseating necrotizing granulomatous infiltrates of epithelioid cells and 
giant cells throughout the upper to middle dermis.  No atypical cell or histiocytic 
palisade surrounding mucin and degenerated collagen was found (Fig. 1d). Stains of 
Periodic acid-Schiff, Grocott methanamine silver, and Ziel-Nielson were all negative. 
Based upon the clinical and histological findings above, the patient was 
diagnosed as cutaneous lichenoid sarcoidosis. Treatment with topical very strong class 
steroid ointment (0.1% mometasone furoate) in accordance with psoralen-ultraviolet A 
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(PUVA) were started, however, the eruptions were refractory to these therapies for over 
one year and extended progressively for the last several months. Since the 
manifestations were limited to the skin, oral administration of tranilast 300 mg/day, 
instead of systemic steroid treatment, was initiated. In response to tranilast, the 
eruptions became smaller and subsided, leaving only pigmentation after the 5-month 
course of this therapy (Fig. 2a, b). 
 Initially, cutaneous sarcoidosis, generalized granuloma annulare (GA), or 
infectious granulomatous diseases was considered for differential diagnosis. 
Generalized GA is occasionally complicated with diabetes mellitus
 
and often shows 
palisades of histiocytes surrounding prominent mucin histologically
1,2
, however, these 
findings were not seen in our case. Infectious granulomas were also excluded by a series 
of examinations on infection. Therefore, we diagnosed this case as the lichenoid type of 
cutaneous sarcoidosis. Topical corticosteroid can be effective to cutaneous sarcoidosis, 
but large or disfiguring lesions may require systemic corticosteroid therapy. Since 




indications for systemic 
corticosteroids should be limited to the patients with vital organ involvements. In our 
case, the skin eruptions, refractory to topical steroids and PUVA therapy, were 
attenuated by the treatment with tranilast. Tranilast, N-3,4-dimethoxycinnamoyl 
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antheranilic acid, is an anti-allergic drug used for the treatment of atopic dermatitis or 
keloid since 1980s. The precise underlying mechanism is unknown, but it has been 
demonstrated that tranilast inhibited the release of chemical mediators and the 
multinucleated giant cell formation of monocytes in vitro.
4
 There has been no report of 
diffusely-scattered lichenoid sarcoidosis treated successfully with tranilast. Although 
limited to a single case, it is considered that tranilast can be a choice for cutaneous 
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Fig 1. Clinical manifestations and histology. (a) Erythematous plaques and 
maculopapules were seen over the whole body (explanatoy; the darky-red lesion (*) is 
hemangioma simplex). (b) Individual lesions were 3- to 5-mm in a diameter, pinkish, 
follicular papules on the abdomen. (c) The clusters of the papules looked like 
erythematous plaques on the upper extremity. (d) Histological examination showed a 
dermal granulomatous infiltrate of epithelioid cells without caseating necrosis. A few 
giant cells and a sparce infiltration of lymphocytes were noted. (hematoxylin and eosin 
staining; magnification 200×.) 
Fig 2. Clinical findings after oral tranilast therapy. After the treatment with tranilast, the 
skin lesions on the abdomen (a) and on the upper extremity (b) were attenuated. 
 


